Aktis Oncology, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly filings show how the company is performing and help investors track progress over time.
Companies announce quarterly earnings to update investors on revenue, losses, and progress toward drug development goals.
New board members bring expertise and oversee management; this shows leadership changes affecting company governance.
Annual results show whether the company made progress, spent money wisely, and stayed on track with plans.
Annual reports give complete details about company finances, operations, and risks that help investors make decisions.
Stocky reads Aktis Oncology, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Aktis Oncology, Inc.'s most recent tracked filing was a 10-Q on 11 May 2026: Filed quarterly results for first quarter 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.